Out of every five children born in Sweden with a diagnosed congenital TORCH infection, roughly one went on to develop autism. That's a striking number on its own, but it's the scale behind it that gives the finding real weight: researchers pulled it from records covering 3.7 million people, virtually the entire population of Sweden born between 1987 and 2021.

The study, published September 21, 2026, in JAMA Pediatrics and led by researchers at the Karolinska Institutet, found that children with a congenital TORCH infection were roughly three times more likely to be diagnosed with autism later in life, and more than seven times more likely to be diagnosed with an intellectual disability, compared with children who weren't infected. For the most severe cases of intellectual disability, the relative risk reached as high as 30 times.

What TORCH infections actually are

TORCH is shorthand for a specific cluster of pathogens, including toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus, capable of crossing the placenta and directly infecting a developing fetus. That's what sets them apart from the far more common infections a pregnant woman might pick up during pregnancy: most maternal infections stay contained to the mother's own body, but TORCH pathogens can breach the placental barrier and reach the fetus directly, according to Karolinska Institutet's own summary of the research.

Out of the 3.7 million people tracked in the study, only 975 had a documented congenital TORCH infection, according to the Karolinska Institutet announcement. That rarity matters enormously for how the findings should be read, and the research team was explicit about keeping that context front and center.

The numbers behind the headline risk

Reneé Gardner, a researcher at Karolinska Institutet's Department of Global Public Health who contributed to the study, summarized the core tension in the data plainly: "They account for a very small proportion of all cases of autism in the population, but for those children who are actually affected, we see a clearly elevated risk of both autism and intellectual disability."

That's a distinction worth sitting with. A threefold relative risk sounds alarming in isolation, but when the underlying condition affects roughly 1 in 3,800 births, as this cohort's 975-in-3.7-million rate suggests, even a threefold increase translates into a small absolute number of additional cases nationwide. The researchers estimated that congenital TORCH infections account for approximately 1.2% of all severe intellectual disability cases in Sweden, and just 0.034% of all autism cases, according to Neuroscience News' coverage of the findings.

Why the researchers still call this actionable

Despite the modest population-level contribution, lead author Hugo Sjöqvist, a doctoral student at Karolinska Institutet, framed the finding as genuinely useful from a public health standpoint, precisely because several TORCH infections are preventable. Rubella, one of the pathogens in the TORCH group, has almost disappeared in Sweden since the country introduced national vaccination programs, according to reporting from russpain.com's coverage of the study, standing as a working proof-of-concept for how prevention can shrink this specific risk category over time.

Other TORCH infections require different prevention strategies. Toxoplasmosis, transmitted through undercooked meat, unwashed vegetables, and contact with cat feces, can largely be avoided through basic food safety and hygiene practices during pregnancy. Cytomegalovirus, the most common congenital infection globally and the leading cause among this group in countries like Sweden and the United States, spreads through bodily fluids, meaning avoiding close contact with young children's saliva and urine during pregnancy can meaningfully reduce exposure risk, according to comments from the research team reported by Newsweek.

A global picture more severe than Sweden's own numbers suggest

Sweden's relatively low TORCH infection rate reflects the country's strong vaccination coverage and healthcare infrastructure, and the researchers were careful not to let that low national baseline obscure the picture elsewhere. Congenital cytomegalovirus alone affects roughly one in every 150 newborns globally, a burden that climbs substantially higher in low- and middle-income countries, according to Euronews' reporting on the study.

That gap points toward where this research carries the most public health weight: not necessarily in Sweden, where robust rubella vaccination has already sharply reduced one major source of TORCH infections, but in regions where vaccination coverage is inconsistent and rubella outbreaks remain more frequent. Sjöqvist noted that infection prevalence varies significantly by country, underscoring that the specific prevention priorities identified in this study, vaccination, hygiene, and food safety, need to be calibrated differently depending on which TORCH pathogens are actually circulating in a given region.

What the study didn't find, and why that matters too

The research team also tested for associations between TORCH infections and other neuropsychiatric conditions, including ADHD and obsessive-compulsive disorder, and found no clear links, according to Technology Networks' coverage of the findings. That negative result adds specificity to the overall picture: this isn't a broad, catch-all risk factor for neurodevelopmental conditions generally, but one that appears concentrated specifically around autism and intellectual disability.

One additional finding extended even to children who weren't diagnosed with either condition. Kids with a congenital TORCH infection but no autism or intellectual disability diagnosis still had, on average, lower academic grades than their peers without the infection, suggesting the developmental impact of these infections may extend along a spectrum broader than formal clinical diagnoses alone capture.

Where the research gaps still are

The study's authors flagged a meaningful limitation in how TORCH infections currently get detected. Newborn screening for these infections isn't universally implemented, even in a country with Sweden's healthcare infrastructure, meaning current systems likely miss asymptomatic cases entirely, according to Euronews' reporting. That detection gap means the true population-level prevalence of congenital TORCH infections, and by extension, their true contribution to autism and intellectual disability rates, is likely underestimated even in this large, register-based study.

Gardner's framing of the overall message strikes a deliberately careful balance: rare fetal infections shouldn't be presented as a broad explanation for autism's rising diagnosis rates, since they account for such a small fraction of overall cases, but their outsized effect on the specific children affected, and the fact that some of these infections are genuinely preventable through vaccination and basic hygiene measures, makes this exactly the kind of finding public health systems can act on without needing to reframe how autism gets understood more broadly. For expectant parents and healthcare providers, the actionable takeaway isn't alarm, it's a reminder that a handful of well-understood, largely preventable infections still deserve consistent screening and prevention focus during pregnancy.